Malignancy Risk Among Psoriasis Patients Treated With Interleukin Inhibitors: A Retrospective Matched-Cohort StudyFebruary 25, 2026Psoriasis
Psoriasis and Obesity: A Clinical Review of the Bidirectional Link and Management ImplicationsFebruary 25, 2026Psoriasis
Safety and Effectiveness of Nonsteroidal Tapinarof Cream 1% Added to Ongoing Biologic Therapy for Treatment of Moderate to Severe Plaque PsoriasisJanuary 13, 2026Psoriasis
Acute Generalized Exanthematous Pustulosis Secondary to Application of Tapinarof Cream 1%October 20, 2025PsoriasisMixed Topics
Apremilast Treatment Outcomes and Adverse Events in Psoriasis Patients With HIVFebruary 5, 2025Psoriasis
The Post-PASI Era: Considering Comorbidities to Select Appropriate Systemic Psoriasis TreatmentsFebruary 3, 2025Psoriasis
Dermatology NewsTreatment with Tildrakizumab Effective for Scalp Psoriasis in Phase 3b StudyJanuary 14, 2025PsoriasisPsoriatic Arthritis
Dermatology NewsCardiac Risks of Newer Psoriasis Biologics vs. TNF Inhibitors ComparedJanuary 7, 2025PsoriasisPsoriatic Arthritis
